Medicaid Coverage For Gilead’s Sovaldi “Imprudent” Unless Price Reduced – Patient Group
This article was originally published in The Pink Sheet Daily
Executive Summary
In response to price concerns with Sovaldi, Gilead Sciences emphasized that “Medicaid, by law, receives very deep discounts, and Gilead is working with each state to complete the necessary steps to ensure a timely review and addition to the state formulary.”
You may also be interested in...
Gilead's Pricing Strategy Faces New Opposition Tactics: Patent, Antitrust Suit
AIDS Healthcare Foundation claims patents covering drug in Genvoya combo are invalid and that Gilead's exclusive licensing deals constitute barriers to trade; Massachusetts AG may pursue unfair trade practice action over Sovaldi pricing.
Sovaldi In Medicaid: Contractor Molina Urges Government To Assume Up-Front Cost
Medicaid managed care organization Molina says its 2014 payment rates are not adequate to cover the cost of Gilead Sciences’ hepatitis C drug Sovaldi and that the government should handle the upfront costs. WellPoint’s Medicaid plans have seen a 50% increase in the cost of treating hepatitis C patients.
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
Bowing to public pressure and following an unusual intervention by FDA, KV Pharmaceuticals announced it has cut the list price of its new preterm birth prevention drug from $1,500 to $690 per injection.